Why Prime Medicine Stock Was Climbing Higher This Week

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.Prime's encouraging news came on Tuesday when the company announced it had launched a preclinical program aimed at treating alpha-1 antitrypsin deficiency (AATD). This is a genetic disorder caused by a mutation in a gene that limits the body's capability to produce a necessary protein and can badly affect the lungs and liver. The ambitious biotech's goal is to file an investigational new drug (IND) and/or clinical trial application (CTA) for this with the U.S. Food and Drug Administration (FDA) in the middle of next year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool